Dizal Pharmaceutical Co., Ltd. (688192.SH) has announced it resubmitted its application to list H-shares on the Main Board of The Stock Exchange of Hong Kong Limited (HKEX) on August 27, 2026, with the corresponding listing documents posted on the HKEX website the same day. This marks the company's renewed effort to pursue a dual listing in Hong Kong after its existing A-share listing on the Shanghai Stock Exchange. The resubmission follows the company's earlier attempt, indicating its continued commitment to expanding its capital market presence and accessing international investors through the Hong Kong platform.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments